Urick, M. E., & Bell, D. W. (2019). Clinical actionability of molecular targets in endometrial cancer. Nature Reviews Cancer, 19(9), 510–521.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu, K. H., & Broaddus, R. R. (2020). Endometrial cancer. The New England Journal of Medicine, 383(21), 2053–2064.

Article  CAS  PubMed  Google Scholar 

Brooks, R. A., Fleming, G. F., Lastra, R. R., Lee, N. K., Moroney, J. W., & Son, C. H., et al. (2019). Current recommendations and recent progress in endometrial cancer. CA: A Cancer Journal for Clinicians, 69(4), 258–279.

PubMed  Google Scholar 

Amant, F., Moerman, P., Neven, P., Timmerman, D., Van Limbergen, E., & Vergote, I. (2005). Endometrial cancer. Lancet., 366(9484), 491–505.

Article  PubMed  Google Scholar 

Abrahams, A., Parker, M. I., & Prince, S. (2010). The T-box transcription factor Tbx2: its role in development and possible implication in cancer. IUBMB Life, 62(2), 92–102.

Article  CAS  PubMed  Google Scholar 

Liu, W. K., Jiang, X. Y., & Zhang, Z. X. (2010). Expression of PSCA, PIWIL1, and TBX2 in endometrial adenocarcinoma. Onkologie, 33(5), 241–245.

Article  CAS  PubMed  Google Scholar 

Wansleben, S., Davis, E., Peres, J., & Prince, S. (2013). A novel role for the anti-senescence factor TBX2 in DNA repair and cisplatin resistance. Cell Death & Disease, 4(10), e846.

Article  CAS  Google Scholar 

Nandana, S., Tripathi, M., Duan, P., Chu, C. Y., Mishra, R., & Liu, C., et al. (2017). Bone metastasis of prostate cancer can be therapeutically targeted at the TBX2-WNT signaling axis. Cancer Research, 77(6), 1331–1344.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu, R., Deng, J., Li, C., Xu, C., Cui, Z. H., & Zhao, J. (2020). Clinical significance of TBX2 in esophageal squamous cell carcinomas and its role in cell migration and invasion. European Review for Medical and Pharmacological Sciences, 24(6), 3062–3068.

CAS  PubMed  Google Scholar 

Hassannia, B., Vandenabeele, P., & Vanden Berghe, T. (2019). Targeting ferroptosis to iron out cancer. Cancer Cell, 35(6), 830–849.

Article  CAS  PubMed  Google Scholar 

Li, J., Cao, F., Yin, H. L., Huang, Z. J., Lin, Z. T., & Mao, N., et al. (2020). Ferroptosis: past, present and future. Cell Death & Disease, 11(2), 88.

Article  Google Scholar 

Lopez-Janeiro A., Ruz-Caracuel I., Ramon-Patino J. L., De Los Rios V., Villalba Esparza M., & Berjon A., et al. (2021). Proteomic analysis of low-grade, early-stage endometrial carcinoma reveals new dysregulated pathways associated with cell death and cell signaling. Cancers, 13(4), 794.

Wang, H., Wu, Y., Chen, S., Hou, M., Yang, Y., & Xie, M. (2021). Construction and validation of a ferroptosis-related prognostic model for endometrial cancer. Frontiers in Genetics, 12, 729046.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei, S., Yu, Z., Shi, R., An, L., Zhang, Q., & Zhang, Q., et al. (2022). GPX4 suppresses ferroptosis to promote malignant progression of endometrial carcinoma via transcriptional activation by ELK1. BMC Cancer, 22(1), 881.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weijiao, Y., Fuchun, L., Mengjie, C., Xiaoqing, Q., Hao, L., & Yuan, L., et al. (2021). Immune infiltration and a ferroptosis-associated gene signature for predicting the prognosis of patients with endometrial cancer. Aging, 13(12), 16713–16732.

Article  PubMed  PubMed Central  Google Scholar 

Ding, N., Zhang, T., Yu, X., & Zhuang, S. (2022). T-box transcription factor 2 enhances chemoresistance of endometrial cancer by mediating NRF2 expression. Current Protein & Peptide Science, 23(8), 563–570.

Article  CAS  Google Scholar 

Seiler, A., Schneider, M., Forster, H., Roth, S., Wirth, E. K., & Culmsee, C., et al. (2008). Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metabolism, 8(3), 237–248.

Article  CAS  PubMed  Google Scholar 

Zhu, M., Jia, N., Nie, Y., Chen, J., Jiang, Y., & Lv, T., et al. (2018). Establishment of patient-derived tumor xenograft models of high-risk endometrial cancer. International Journal of Gynecological Cancer, 28(9), 1812–1820.

Article  PubMed  Google Scholar 

Sato, M., Kusumi, R., Hamashima, S., Kobayashi, S., Sasaki, S., & Komiyama, Y., et al. (2018). The ferroptosis inducer erastin irreversibly inhibits system x(c)- and synergizes with cisplatin to increase cisplatin’s cytotoxicity in cancer cells. Scientific Reports, 8(1), 968.

Article  PubMed  PubMed Central  Google Scholar 

Doll, S., Freitas, F. P., Shah, R., Aldrovandi, M., da Silva, M. C., & Ingold, I., et al. (2019). FSP1 is a glutathione-independent ferroptosis suppressor. Nature, 575(7784), 693–698.

Article  CAS  PubMed  Google Scholar 

Li, L., Qiu, C., Hou, M., Wang, X., Huang, C., & Zou, J., et al. (2021). Ferroptosis in ovarian cancer: a novel therapeutic strategy. Frontiers in Oncology, 11, 665945.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheu J. W., Lee D., Li Q., Goh C. C., Bao M. H., & Yuen V. W., et al. (2023). Ferroptosis suppressor protein 1 inhibition promotes tumor ferroptosis and anti-tumor immune responses in liver cancer. Cell Mol Gastroenterol Hepatol, 16, 133–159.

Emmanuel, N., Li, H., Chen, J., & Zhang, Y. (2022). FSP1, a novel KEAP1/NRF2 target gene regulating ferroptosis and radioresistance in lung cancers. Oncotarget, 13, 1136–1139.

Article  PubMed  PubMed Central  Google Scholar 

Jo, A., Bae, J. H., Yoon, Y. J., Chung, T. H., Lee, E. W., & Kim, Y. H., et al. (2022). Plasma-activated medium induces ferroptosis by depleting FSP1 in human lung cancer cells. Cell Death & Disease, 13(3), 212.

Article  CAS  Google Scholar 

Koppula, P., Lei, G., Zhang, Y., Yan, Y., Mao, C., & Kondiparthi, L., et al. (2022). A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers. Nature Communications, 13(1), 2206.

Article  CAS  PubMed  PubMed Central  Google Scholar